眼高压治疗市场 - 全球产业规模、份额、趋势、机会和预测，按类型、给药途径、配销通路、地区和竞争细分，2020-2030 年

2024 年全球眼高压治疗市场价值为 36.7 亿美元，预计在预测期内将经历强劲增长，到 2030 年的年复合成长率(CAGR) 为 3.82%。近年来，受眼高压盛行率上升和对先进治疗方案的需求不断增加的推动，该市场取得了显着发展。眼高压的特征是眼压升高，如果不及时治疗，会导致青光眼——世界范围内不可逆失明的主要原因之一。因此，眼高压治疗市场是眼科保健领域的重要部分。例如，2024 年 1 月，印第安纳大学医学院的研究人员启动了一项创新计划，旨在开发突破性的青光眼治疗方法，该计划得到了美国国家眼科研究所 200 万美元 R01 资助。

主要市场驱动因素：

人口老化

主要市场挑战：

诊断不足和缺乏认识

主要市场趋势：

微创手术技术

目录

第 1 章：产品概述

第 2 章：研究方法

第 3 章：执行摘要

第四章：全球眼高压治疗市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 按类型（眼压过高、青光眼）
  • 依给药途径（口服、肠胃外、其他）
  • 按配销通路（零售药局、网路药局、其他）
  • 按地区
  • 按公司分类（2024）
• 市场地图
  • 按类型
  • 依给药途径
  • 按配销通路
  • 按地区

第 5 章：亚太地区眼高压治疗市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 按类型
  • 依给药途径
  • 按配销通路
  • 按国家
• 亚太地区：国家分析
  • 中国
  • 印度
  • 澳洲
  • 日本
  • 韩国

第六章：欧洲眼高压治疗市场展望

• 市场规模和预测
• 市场占有率和预测
• 欧洲：国家分析
  • 德国
  • 西班牙
  • 义大利
  • 英国

第 7 章：北美眼高压治疗市场展望

• 市场规模和预测
• 市场占有率和预测
• 北美：国家分析
  • 墨西哥
  • 加拿大

第 8 章：南美洲眼高压治疗市场展望

• 市场规模和预测
• 市场占有率和预测
• 南美洲：国家分析
  • 阿根廷
  • 哥伦比亚

第 9 章：中东和非洲眼高压治疗市场展望

• 市场规模和预测
• 市场占有率和预测
• MEA：国家分析
  • 沙乌地阿拉伯
  • 阿联酋

第 10 章：市场动态

• 驱动程式
• 挑战

第 11 章：市场趋势与发展

• 最新动态
• 产品发布
• 合併与收购

第 12 章：全球眼高压治疗市场：SWOT 分析

第 13 章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的力量
• 顾客的力量
• 替代产品的威胁

第 14 章：竞争格局

• Angelini Spa
• Laboratorios Sophia
• Neurim Pharmaceuticals Ltd
• Nicox SA
• Novartis AG.
• Aerie Pharmaceuticals, Inc.
• Abbvie, Inc
• Angelini Pharma Spa
• Chong Kun Dang pharmaceutical Corp
• Lee Pharma Ltd

第 15 章：策略建议

第16章调查会社について・免责事项

The global Ocular Hypertension Treatment Market was valued at USD 3.67 billion in 2024 and is projected to experience robust growth during the forecast period, with a compound annual growth rate (CAGR) of 3.82% through 2030. The market has seen significant development in recent years, driven by the rising prevalence of ocular hypertension and the increasing demand for advanced therapeutic solutions. Ocular hypertension is characterized by elevated intraocular pressure, which, if left untreated, can lead to glaucoma-one of the leading causes of irreversible blindness worldwide. As a result, the ocular hypertension treatment market is a critical segment of the ophthalmic healthcare sector. For example, in January 2024, researchers at Indiana University School of Medicine launched an innovative initiative to develop groundbreaking therapy for glaucoma, supported by a USD 2 million R01 grant from the National Eye Institute.

Key Market Drivers:

Aging Population

The growing aging population is a key driver of the expanding global ocular hypertension treatment market. As individuals age, they become more susceptible to ocular hypertension due to age-related changes in the eye's drainage system, which can hinder the flow of aqueous humor and increase intraocular pressure. The World Health Organization forecasts that the global population aged 60 and older will more than double by 2050, reaching nearly 2.1 billion people. This demographic shift will result in a rise in the prevalence of ocular hypertension and glaucoma among the elderly, creating a larger patient base in need of treatment. As the population ages, there will be an increased demand for both pharmaceutical and surgical interventions, including minimally invasive procedures like Micro-Invasive Glaucoma Surgery (MIGS). These treatments offer less invasive and more efficient solutions for managing intraocular pressure. Consequently, the global ocular hypertension treatment market is positioned for steady growth, catering to the rising healthcare needs of older individuals and contributing to better vision preservation and reduced blindness rates.

Key Market Challenges:

Underdiagnosis and Lack of Awareness

Ocular hypertension is often a silent condition, with no obvious symptoms, making it challenging to detect early. Many individuals are unaware of the condition and its potential progression to glaucoma, which leads to a delay in diagnosis and intervention. This lack of awareness poses a significant barrier to market growth, as untreated ocular hypertension can advance to glaucoma, resulting in irreversible vision loss. Public ignorance about the importance of regular eye check-ups further complicates early detection efforts. Raising awareness about ocular hypertension and its connection to glaucoma is essential for capturing potential patients early, when treatments are most effective. Healthcare professionals, ophthalmologists, and public health campaigns must play a key role in educating individuals about the risks of ocular hypertension and the need for proactive eye care.

Key Market Trends:

Minimally Invasive Surgical Techniques

Minimally invasive surgical techniques are transforming the treatment landscape for ocular hypertension. Traditionally, managing elevated intraocular pressure involved more invasive surgeries, often with longer recovery times and higher risks. However, the development of Micro-Invasive Glaucoma Surgery (MIGS) has introduced a less invasive approach that reduces surgical trauma while targeting the underlying causes of elevated intraocular pressure. MIGS has numerous benefits for both patients and healthcare providers, including shorter recovery periods, lower complication rates, and improved patient outcomes. The growing adoption of MIGS is expected to continue driving the ocular hypertension treatment market, providing a shift toward more efficient and patient-friendly treatment options.

Key Market Players:

• Angelini Spa
• Laboratorios Sophia
• Neurim Pharmaceuticals Ltd
• Nicox SA
• Novartis AG
• Aerie Pharmaceuticals, Inc.
• AbbVie, Inc.
• Angelini Pharma S.p.a.
• Chong Kun Dang Pharmaceutical Corp
• Lee Pharma Ltd

Report Scope:

This report segments the global ocular hypertension treatment market into various categories and provides a detailed analysis of trends:

By Type:

• Intraocular Hypertension
• Glaucoma

By Route of Administration:

• Oral
• Parenteral
• Other

By Distribution Channel:

• Retail Pharmacy
• Online Pharmacy
• Other

By Region:

• North America: United States, Canada, Mexico
• Europe: France, United Kingdom, Italy, Germany, Spain
• Asia-Pacific: China, India, Japan, Australia, South Korea
• South America: Brazil, Argentina, Colombia
• Middle East & Africa: South Africa, Saudi Arabia, UAE

Competitive Landscape:

This section provides a comprehensive analysis and profiling of major companies operating in the global ocular hypertension treatment market.

Available Customizations:

TechSci Research offers tailored customization options for this market report, allowing adjustments to meet specific company needs. Customization options include detailed analysis and profiling of up to five additional market players.

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Ocular Hypertension Treatment Market Outlook

• 4.1. Market Size & Forecast
  • 4.1.1. By Value
• 4.2. Market Share & Forecast
  • 4.2.1. By Type (Intraocular Hypertension, Glaucoma)
  • 4.2.2. By Route Of Administration (Oral, Parenteral, Other)
  • 4.2.3. By Distribution Channel (Retail Pharmacy, Online Pharmacy, Other)
  • 4.2.4. By Region
  • 4.2.5. By Company (2024)
• 4.3. Market Map
  • 4.3.1. By Type
  • 4.3.2. By Route Of Administration
  • 4.3.3. By Distribution Channel
  • 4.3.4. By Region

5. Asia Pacific Ocular Hypertension Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type
  • 5.2.2. By Route Of Administration
  • 5.2.3. By Distribution Channel
  • 5.2.4. By Country
• 5.3. Asia Pacific: Country Analysis
  • 5.3.1. China Ocular Hypertension Treatment Market Outlook
    • 5.3.1.1. Market Size & Forecast
      • 5.3.1.1.1. By Value
    • 5.3.1.2. Market Share & Forecast
      • 5.3.1.2.1. By Type
      • 5.3.1.2.2. By Route Of Administration
      • 5.3.1.2.3. By Distribution Channel
  • 5.3.2. India Ocular Hypertension Treatment Market Outlook
    • 5.3.2.1. Market Size & Forecast
      • 5.3.2.1.1. By Value
    • 5.3.2.2. Market Share & Forecast
      • 5.3.2.2.1. By Type
      • 5.3.2.2.2. By Route Of Administration
      • 5.3.2.2.3. By Distribution Channel
  • 5.3.3. Australia Ocular Hypertension Treatment Market Outlook
    • 5.3.3.1. Market Size & Forecast
      • 5.3.3.1.1. By Value
    • 5.3.3.2. Market Share & Forecast
      • 5.3.3.2.1. By Type
      • 5.3.3.2.2. By Route Of Administration
      • 5.3.3.2.3. By Distribution Channel
  • 5.3.4. Japan Ocular Hypertension Treatment Market Outlook
    • 5.3.4.1. Market Size & Forecast
      • 5.3.4.1.1. By Value
    • 5.3.4.2. Market Share & Forecast
      • 5.3.4.2.1. By Type
      • 5.3.4.2.2. By Route Of Administration
      • 5.3.4.2.3. By Distribution Channel
  • 5.3.5. South Korea Ocular Hypertension Treatment Market Outlook
    • 5.3.5.1. Market Size & Forecast
      • 5.3.5.1.1. By Value
    • 5.3.5.2. Market Share & Forecast
      • 5.3.5.2.1. By Type
      • 5.3.5.2.2. By Route Of Administration
      • 5.3.5.2.3. By Distribution Channel

6. Europe Ocular Hypertension Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Route Of Administration
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
• 6.3. Europe: Country Analysis
  • 6.3.1. France Ocular Hypertension Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Route Of Administration
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Germany Ocular Hypertension Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Route Of Administration
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Spain Ocular Hypertension Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Route Of Administration
      • 6.3.3.2.3. By Distribution Channel
  • 6.3.4. Italy Ocular Hypertension Treatment Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Type
      • 6.3.4.2.2. By Route Of Administration
      • 6.3.4.2.3. By Distribution Channel
  • 6.3.5. United Kingdom Ocular Hypertension Treatment Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Type
      • 6.3.5.2.2. By Route Of Administration
      • 6.3.5.2.3. By Distribution Channel

7. North America Ocular Hypertension Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Route Of Administration
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States Ocular Hypertension Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Route Of Administration
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. Mexico Ocular Hypertension Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Route Of Administration
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. Canada Ocular Hypertension Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Route Of Administration
      • 7.3.3.2.3. By Distribution Channel

8. South America Ocular Hypertension Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Route Of Administration
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. South America: Country Analysis
  • 8.3.1. Brazil Ocular Hypertension Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Route Of Administration
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. Argentina Ocular Hypertension Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Route Of Administration
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. Colombia Ocular Hypertension Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Route Of Administration
      • 8.3.3.2.3. By Distribution Channel

9. Middle East and Africa Ocular Hypertension Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Route Of Administration
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. MEA: Country Analysis
  • 9.3.1. South Africa Ocular Hypertension Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Route Of Administration
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. Saudi Arabia Ocular Hypertension Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Route Of Administration
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. UAE Ocular Hypertension Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Route Of Administration
      • 9.3.3.2.3. By Distribution Channel

10. Market Dynamics

• 10.1. Drivers
• 10.2. Challenges

11. Market Trends & Developments

• 11.1. Recent Developments
• 11.2. Product Launches
• 11.3. Mergers & Acquisitions

12. Global Ocular Hypertension Treatment Market: SWOT Analysis

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Product

14. Competitive Landscape

• 14.1. Angelini Spa
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (In case of listed)
  • 14.1.5. Recent Developments
  • 14.1.6. SWOT Analysis
• 14.2. Laboratorios Sophia
• 14.3. Neurim Pharmaceuticals Ltd
• 14.4. Nicox SA
• 14.5. Novartis AG.
• 14.6. Aerie Pharmaceuticals, Inc.
• 14.7. Abbvie, Inc
• 14.8. Angelini Pharma S.p.a.
• 14.9. Chong Kun Dang pharmaceutical Corp
• 14.10. Lee Pharma Ltd

15. Strategic Recommendations

16. About Us & Disclaimer